DEVELOPMENT OF CANADIAN SCREENING TOOLS FOR FETAL ALCOHOL SPECTRUM DISORDER

被引:0
作者
Goh, Y. Ingrid [1 ,2 ]
Chudley, Albert E. [3 ,4 ]
Clarren, Sterling K. [5 ,6 ]
Koren, Gideon [1 ,2 ,7 ,8 ]
Orrbine, Elaine [9 ]
Rosales, Ted [10 ]
Rosenbaum, Charlotte [11 ]
机构
[1] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Motherisk Program, Toronto, ON, Canada
[2] Univ Toronto, Dept Pharmaceut Sci, Toronto, ON, Canada
[3] Univ Manitoba, Dept Pediat & Child Hlth & Biochem & Med Genet, Winnipeg, MB, Canada
[4] Winnipeg Reg Hlth Author, Program Genet & Metab, Winnipeg, MB, Canada
[5] Canada Northwest FASD Res Network, Vancouver, BC, Canada
[6] Univ British Columbia, Ctr Community Child Hlth Res, Vancouver, BC, Canada
[7] Univ Toronto, Fac Med, Toronto, ON, Canada
[8] Univ Western Ontario, Dept Med, Div Clin Pharmacol, London, ON, Canada
[9] CAPHC, Ottawa, ON, Canada
[10] Mem Univ Newfoundland, Fac Med, Dept Pediat, St John, NF, Canada
[11] Charlotte Rosenbaum Consulting Serv, Kingston, ON, Canada
来源
JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY | 2008年 / 15卷 / 02期
关键词
Fetal alcohol spectrum disorder; screening;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fetal alcohol spectrum disorder (FASD) is the most common cause of neurobehavioural handicap in North America. Screening for FASD may facilitate diagnosis and hence management of these children. We present a variety of screening tools for the identification of children at risk for FASD. Methods We critically reviewed and evaluated published and practiced methods for their potential of screening suspected cases, their epidemiological characteristics (sensitivity, specificity, positive and negative predictive values) [Phase I], as well as their feasibility [Phase II]. Results The following five tools were selected for the FASD screening toolkit: screening fatty acid ethyl esters in neonatal meconium, the modified Child Behaviour Checklist, Medicine Wheel tool, Asante Centre Probation Officer Tool, and maternal history of drinking and drug use. Conclusions The toolkit for FASD screening aims at screening different populations, from the newborns to youth and at-risk mothers. It is anticipated that the toolkit will facilitate diagnosis of FASD.
引用
收藏
页码:E344 / E366
页数:23
相关论文
共 34 条
  • [1] [Anonymous], 1968, PRINCIPLES PRACTICE
  • [2] Diagnosing the full spectrum of fetal alcohol-exposed individuals: Introducing the 4-Digit Diagnostic Code
    Astley, SJ
    Clarren, SK
    [J]. ALCOHOL AND ALCOHOLISM, 2000, 35 (04): : 400 - 410
  • [3] Application of the fetal alcohol syndrome facial photographic screening tool in a foster care population
    Astley, SJ
    Stachowiak, J
    Clarren, SK
    Clausen, C
    [J]. JOURNAL OF PEDIATRICS, 2002, 141 (05) : 712 - 717
  • [4] Validation of a new biomarker of fetal exposure to alcohol
    Bearer, CF
    Jacobson, JL
    Jacobson, SW
    Barr, D
    Croxford, J
    Molteno, CD
    Viljoen, DL
    Marais, AS
    Chiodo, LM
    Cwik, AS
    [J]. JOURNAL OF PEDIATRICS, 2003, 143 (04) : 463 - 469
  • [5] Ethyl linoleate in meconium: A biomarker for prenatal ethanol exposure
    Bearer, CF
    Lee, S
    Salvator, AE
    Minnes, S
    Swick, A
    Yamashita, T
    Singer, LT
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1999, 23 (03) : 487 - 493
  • [6] Chronic prenatal ethanol exposure and increased concentration of fatty acid ethyl esters in meconium of term fetal guinea pig
    Brien, JF
    Chan, D
    Green, CR
    Iqbal, U
    Gareri, J
    Kobus, SM
    McLaughlin, BE
    Klein, J
    Rao, C
    Reynolds, JN
    Bocking, AD
    Koren, G
    [J]. THERAPEUTIC DRUG MONITORING, 2006, 28 (03) : 345 - 350
  • [7] Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P1178
  • [8] Validation of meconium fatty acid ethyl esters as biomarkers of prenatal alcohol exposure
    Chan, D
    Klein, J
    Koren, G
    [J]. JOURNAL OF PEDIATRICS, 2004, 144 (05) : 692 - 692
  • [9] Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto
    Chan, D
    Bar-Oz, B
    Pellerin, B
    Paciorek, C
    Klein, J
    Kapur, B
    Farine, D
    Koren, G
    [J]. THERAPEUTIC DRUG MONITORING, 2003, 25 (03) : 271 - 278
  • [10] Chavez G F, 1988, MMWR CDC Surveill Summ, V37, P17